Award
Definitive Contract #75F40126C00093
Definitive Contract for AI-Driven Pharmaceutical Process Platform
Buyer
Food and Drug Administration
Award Amount
$456,721.00
Ceiling
$456,721.00
Awarded
September 30, 2026
Period of Performance
Sep 30, 2026 – Sep 29, 2028
Identifier
75F40126C00093
NAICS
541714
This definitive contract was awarded to the University of Massachusetts Lowell, a reputable academic institution specializing in advanced research and technology development. The contract involves providing research and development services to design, develop, validate, and deliver an AI-assisted digital twin platform focused on pharmaceutical lyophilization process development and scale-up. This innovative platform is significant for enhancing pharmaceutical manufacturing efficiency and scalability, addressing critical needs in drug preservation and production. The contract scope covers all aspects of the AI platform lifecycle, including initial design, validation of functionalities, and final delivery tailored to pharmaceutical applications. Awarded through competitive procurement, this contract enables the agency to leverage cutting-edge AI technology from a leading research entity. The work will be performed in Silver Spring, Maryland, spanning a multi-year period to ensure thorough development and deployment of the platform.
Description
TO PROVIDE RESEARCH AND DEVELOPMENT SERVICES TO DESIGN, DEVELOP, VALIDATE, AND DELIVER AN AI-ASSISTED DIGITAL TWIN PLATFORM FOR PHARMACEUTICAL LYOPHILIZATION PROCESS DEVELOPMENT AND SCALE-UP.